Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10415 (
Bcl-2
)
33,771
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The p53 tumor suppressor protein plays a crucial role in tumorigenesis by controlling cell-cycle progression and apoptosis. We have previously described a transcript designated
tumor suppressor activated pathway-6
(
TSAP6
) that is up-regulated in the p53-inducible cell line, LTR6. Cloning of the murine and human full-length
TSAP6
cDNA revealed that it encodes a 488-aa protein with five to six transmembrane domains. This gene is the murine and human homologue of the recently published rat
pHyde
. Antibodies raised against murine and human
TSAP6
recognize a 50- to 55-kDa band induced by p53. Analysis of the
TSAP6
promoter identified a functional p53-responsive element. Functional studies demonstrated that
TSAP6
antisense cDNA diminished levels of the 50- to 55-kDa protein and decreased significantly the levels of p53-induced apoptosis. Furthermore,
TSAP6
small interfering RNA inhibited apoptosis in
TSAP6
-overexpressing cells. Yeast two-hybrid analysis followed by GST/in vitro-transcribed/translated pull-down assays and in vivo coimmunoprecipitations revealed that
TSAP6
associated with Nix, a proapoptotic
Bcl-2
-related protein and the Myt1 kinase, a negative regulator of the G(2)/M transition. Moreover,
TSAP6
enhanced the susceptibility of cells to apoptosis and cooperated with Nix to exacerbate this effect. Cell-cycle studies indicated that
TSAP6
could augment Myt1 activity. Overall, these data suggest that
TSAP6
may act downstream to p53 to interface apoptosis and cell-cycle progression.
...
PMID:The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. 1260 22
We have previously reported that rhomboid domain containing 1 (RHBDD1), a mammalian rhomboid protease highly expressed in the testis, can cleave the
Bcl-2
protein Bik. In this study, we identified a multi-pass transmembrane protein,
tumor suppressor activated pathway-6
(
TSAP6
) as a potential substrate of RHBDD1. RHBDD1 was found to induce the proteolysis of
TSAP6
in a dose- and activity-dependent manner. The cleavage of
TSAP6
was not restricted to its glycosylated form and occurred in three different regions. In addition, mass spectrometry and mutagenesis analyses both indicated that the major cleavage site laid in the C-terminal of the third transmembrane domain of
TSAP6
. A somatic cell knock-in approach was used to genetically inactivate the endogenous RHBDD1 in HCT116 and RKO colon cancer cells. Exosome secretion was significantly elevated when RHBDD1 was inactivated in the two cells lines. The increased exosome secretion was verfied through the detection of certain exosomal components, including Tsg101, Tf-R, FasL and Trail. In addition, the elevation of exosome secretion by RHBDD1 inactivation was reduced when
TSAP6
was knocked down, indicating that the role of RHBDD1 in regulating exosomal trafficking is very likely to be
TSAP6
-dependent. We found that the increase in FasL and Trail increased exosome-induced apoptosis in Jurkat cells. Taken together, our findings suggest that RHBDD1 is involved in the regulation of a nonclassical exosomal secretion pathway through the restriction of
TSAP6
.
...
PMID:Exosome-related multi-pass transmembrane protein TSAP6 is a target of rhomboid protease RHBDD1-induced proteolysis. 2262 35